Lycera and Merck Reach Milestone in Collaboration for IBD Therapy

Lycera and Merck Reach Milestone in Collaboration for IBD Therapy
Lycera Corp. has reached a milestone in its collaboration agreement with Merck on the study and development of small molecule therapeutic candidates to address a series of immune-mediated disorders, including inflammatory bowel diseases (IBD). Both companies believe that the milestone is a sign of the success of their partnership, which will continue conducting clinical investigations. Lycera has disclosed another payment,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *